




AUG 30 2006

<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>					Docket No. <b>060525-5001-00</b>	
Applicant(s): <b>Kumar et al</b>						
Application No. <b>10/723,654</b>	Filing Date <b>November 26, 2003</b>	Examiner <b>Alstrum-Acevedo</b>	Customer No.	Group Art Unit <b>1615</b>	Confirmation No.	
Invention: <b>METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF OPIOID CONTAINING DOSAGE FORMS</b>						
<b><u>COMMISSIONER FOR PATENTS:</u></b>						
Transmitted herewith is an amendment in the above-identified application.						
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27						
The fee has been calculated and is transmitted as shown below.						
<b>CLAIMS AS AMENDED</b>						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
<b>TOTAL CLAIMS</b>	53 -	57 -	0	x \$25.00	\$0.00	
<b>INDEP. CLAIMS</b>	3 -	6 -	0	x \$100.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>	
<input type="checkbox"/> No additional fee is required for amendment. <input checked="" type="checkbox"/> Please charge Deposit Account No. <b>50-0310</b> in the amount of <b>\$0.00</b> <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>50-0310</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>						
 <b>Christopher I. Halliday, Reg. No. 42,621</b> <b>MORGAN, LEWIS &amp; BOCKIUS LLP</b> <b>1701 Market Street</b> <b>Philadelphia, PA 19103</b>  <b>Tele: (215) 963-5337</b> <b>Fax: (215) 963-5001</b>			Dated: <b>August 30, 2006</b>  <div style="border: 1px solid black; padding: 10px; margin-top: 10px;"> I certify that this correspondence is being submitted to the "Commissioner for Patents" via facsimile (571)273-8300 on <b>August 30, 2006</b>     Signature of Person Mailing Correspondence  <b>Christopher I. Halliday</b>  <small>Printed Name of Person Mailing Correspondence</small> </div>			

cc:

AUG 30 2006

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FAX FILED TO THE COMMISSIONER OF PATENTS AT (571)-273-8300 ON THE DATE INDICATED BELOW.

BY:  DATE: 8/30/06

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Patent Application of Vijai Kumar et al.	: Group Art Unit: 1615 : :
Appln. No.:	10/723,654	: Examiner Alstrum-Acevedo : :
Filed:	November 26, 2003	: Attorney Docket : :
For:	METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF OPIOID CONTAINING DOSAGE FORMS	: No. 060525-5001-00 : :

**RESPONSE TO THE OFFICE ACTION DATED MAY 30, 2006**

This Response is in reply to the Office Action mailed on May 30, 2006, in connection with the above above-referenced application. This Response is being timely filed.

Please consider the following Remarks intended to place the application in condition for allowance. Reconsideration of the application is respectfully requested.

The Listing of Claims begins on page 2 and the Remarks begin on page 8.